Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 1Phase 1/2 1

Status

Unknown 7Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Gastrointestinal 7

Conditions

Carcinoma, Non-Small-Cell Lung 26Small Cell Lung Carcinoma 10Sarcoma 8Breast Neoplasms 8Carcinoma, Hepatocellular 7Lung Neoplasms 6Stomach Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Esophageal Squamous Cell Carcinoma 4Carcinoma 4Non-squamous Non-small Cell Lung Cancer 3NSCLC 3Glioma 3Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Thyroid Neoplasms 2Pheochromocytoma 2Paraganglioma 2Neoplasms 2Liver Neoplasms 2Gynecological Cancer 2Extensive Stage Small Cell Lung Cancer 2Esophageal Neoplasms 2Endometrial Neoplasms 2Digestive System Neoplasms 2Carcinoma, Ovarian Epithelial 2Advanced Solid Tumor 2Squamous Non-small Cell Lung Cancer 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Sorafenib 46lenvatinib 44apatinib 23sintilimab 22Fluorouracil 21camrelizumab 20Oxaliplatin 17Radiofrequency Ablation 16Radiosurgery 15Hepatectomy 15tislelizumab 14Leucovorin 14Radiotherapy 12Doxorubicin 12toripalimab 11Folfox protocol 10Bevacizumab 10Immune Checkpoint Inhibitors 9Epirubicin 9regorafenib 8Ethiodized Oil 8durvalumab 7donafenib 7anlotinib 7Neoadjuvant Therapy 7pembrolizumab 6entecavir 6Surgical Procedures, Operative 6Nivolumab 6Injections 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Hepatocellular × anlotinib × Clear all
NCT06031480 2023-09-11

FAITH

Shanghai Zhongshan Hospital

Phase 2 Unknown
55 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04665609 2021-03-04

Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC

Chinese PLA General Hospital

Phase 3 Unknown
80 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04080154 2020-04-03

ALTER-H-002

Shanghai Zhongshan Hospital

Phase 2 Unknown
28 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04157140 2019-12-03

Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC

Beijing Ditan Hospital

Phase 2 Unknown
48 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03825705 2019-10-31

A Study on Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Patients With Advanced Biliary Adenocarcinoma/Hepatocellular Carcinoma

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04066543 2019-08-26

TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients

Zhejiang Cancer Hospital

Phase 2 Unknown
40 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT02809534 2016-09-07

ALTER0802

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Unknown
60 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡